FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome With Excess Blasts
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Pretargeted Radioimmunotherapy
Radiation: Total-Body Irradiation
Procedure: Biospecimen Collection
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2017-04-25

Last Posted Date: 2025-03-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 75

Registration Number: NCT03128034

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant

Phase 3

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Internet, Mobile app and Telehealth Intervention
Other: Best Practice and Internet site with links to existing resources
Other: Survey Administration

First Posted Date: 2017-04-24

Last Posted Date: 2025-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 546

Registration Number: NCT03125070

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 12 locations

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory B Acute Lymphoblastic Leukemia
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Other: Pharmacological Study

First Posted Date: 2017-04-07

Last Posted Date: 2024-04-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 55

Registration Number: NCT03103971

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Communicating Health Information and Improving Coordination With Primary Care

Not Applicable

Completed

Conditions: Diabetes
Dyslipidemias
Childhood Cancer
Hypertension

Interventions: Behavioral: Test results only
Behavioral: Education

First Posted Date: 2017-04-07

Last Posted Date: 2024-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 347

Registration Number: NCT03104543

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Phase 1

Terminated

Conditions: Metastatic Liposarcoma
Unresectable Leiomyosarcoma
Unresectable Liposarcoma
Metastatic Leiomyosarcoma

Interventions: Drug: Avelumab
Drug: Trabectedin

First Posted Date: 2017-03-08

Last Posted Date: 2022-04-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03074318

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

Phase 4

Terminated

Conditions: High Grade Anal Canal Intraepithelial Neoplasia
High Grade Vulvar Squamous Intraepithelial Lesion

Interventions: Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Other: Placebo Administration
Biological: Recombinant Human Papillomavirus Nonavalent Vaccine

First Posted Date: 2017-02-13

Last Posted Date: 2024-02-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 188

Registration Number: NCT03051516

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer

Not Applicable

Terminated

Conditions: Advanced Malignant Neoplasm

Interventions: Other: Communication Intervention
Other: Questionnaire Administration

First Posted Date: 2017-02-10

Last Posted Date: 2021-11-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT03049397

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Together We STRIDE (Strategizing Together Relevant Interventions for Diet and Exercise)

Not Applicable

Completed

Conditions: Obesity, Childhood

Interventions: Behavioral: Multi-Level Intervention
Behavioral: Genetic Newsletters

First Posted Date: 2016-12-05

Last Posted Date: 2021-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 888

Registration Number: NCT02982759

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Anemia

Interventions: Drug: Deferasirox
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-10-25

Last Posted Date: 2020-07-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT02943668

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Phase 1

Completed

Conditions: Mixed Phenotype Acute Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Recurrent High Risk Myelodysplastic Syndrome
Refractory High Risk Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Decitabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2016-09-30

Last Posted Date: 2020-03-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 28

Registration Number: NCT02921061

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy